Affinity at 5-HT2A approximately 60 times higher than at dopamine D21,2*
High 5-HT2A/D2 occupancy ratio allows for lower amounts of dopamine D2 antagonism at therapeutic doses3
The antipsychotic activity of CAPLYTA is thought to be mediated through a combination of antagonism of serotonin 5-HT2A receptors and postsynaptic antagonism of dopamine D2 receptors. The mechanism of action of CAPLYTA is unknown.1
High 5-HT2A/D2 occupancy ratio allows for lower amounts of dopamine D2 antagonism at therapeutic doses3
*5-HT2A (Ki=0.48 nM); D2 (Ki=47 nM); human recombinant receptor expressed in HEK-293 cells. Observed values may vary.2
Helpful tools & resources
References: 1. CAPLYTA prescribing information, 2022. 2. Data on File. 2021. 3. Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016(6):601-614. 4. Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (Barc). 2018;54(12):713-719.